Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
hpkQkcCmYgzg8cnE
Listen
